Critical appraisal of the role of rituximab in the treatment of patients with previously untreated or treated chronic lymphocytic leukemia (CLL)

Patients with chronic lymphocytic leukemia (CLL) have benefited from the introduction of targeted therapy for leukemia. Rituximab (a chimeric murine-derived monoclonal antibody that targets CD20 on lymphocytes) was the first monoclonal antibody to affect the natural course of this disease. Several r...

Descripción completa

Detalles Bibliográficos
Autores principales: Al-Kali, Aref, Wierda, William, Keating, Michael, O’Brien, Susan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2010
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3262335/
https://www.ncbi.nlm.nih.gov/pubmed/22282690

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3262335/
https://www.ncbi.nlm.nih.gov/pubmed/22282690

Ejemplares similares